MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Amicus Therapeutics Inc

Chiusa

SettoreSettore sanitario

6.1 3.57

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

6.03

Massimo

6.1

Metriche Chiave

By Trading Economics

Entrata

-36M

-22M

Vendite

-24M

125M

Margine di Profitto

-17.314

Dipendenti

499

EBITDA

-27M

-4.8M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+178.69% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-506M

1.8B

Apertura precedente

2.53

Chiusura precedente

6.1

Notizie sul Sentiment di mercato

By Acuity

50%

50%

115 / 375 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Amicus Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 lug 2025, 04:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

4 lug 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

4 lug 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

4 lug 2025, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

4 lug 2025, 20:50 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

4 lug 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

4 lug 2025, 16:20 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

4 lug 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

4 lug 2025, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

4 lug 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

4 lug 2025, 15:57 UTC

Discorsi di Mercato

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 lug 2025, 15:49 UTC

Discorsi di Mercato

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 lug 2025, 15:49 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 lug 2025, 15:49 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 lug 2025, 15:49 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole Received All Required Authorizations

4 lug 2025, 15:48 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 lug 2025, 15:47 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole: Agreement Was Announced on Dec. 19

4 lug 2025, 15:47 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 lug 2025, 15:46 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 lug 2025, 14:30 UTC

Acquisizioni, Fusioni, Takeovers

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 lug 2025, 13:53 UTC

Discorsi di Mercato

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 lug 2025, 13:41 UTC

Discorsi di Mercato

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 lug 2025, 13:41 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

4 lug 2025, 13:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

4 lug 2025, 12:37 UTC

Discorsi di Mercato

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 lug 2025, 12:37 UTC

Discorsi di Mercato

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 lug 2025, 12:30 UTC

Discorsi di Mercato

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 lug 2025, 12:15 UTC

Discorsi di Mercato

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 lug 2025, 12:13 UTC

Discorsi di Mercato

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 lug 2025, 12:02 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Amicus Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

178.69% in crescita

Previsioni per 12 mesi

Media 17 USD  178.69%

Alto 22 USD

Basso 13 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Amicus Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

7 ratings

6

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

5.925 / 7.38Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

115 / 375 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.